ZYUS Life Sciences Corporation
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
51.2M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.
Healthcare
Drug Manufacturers - Specialty & Generic
TSXV
Key Financial Metrics
481,000
Revenue
-33.8M
Net Income
C$-0.47
EPS (Diluted)
-9.9M
Free Cash Flow
Profitability
Gross Margin
26.8%
Operating Margin
-3056.1%
Net Profit Margin
-7028.1%
EBITDA
-32.2M
Returns & Efficiency
Return on Assets (ROA)
-230.4%
Return on Equity (ROE)
-
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
14.7M
Total Debt
12.2M
Debt to Equity
-
Current Ratio
0.19
Company Info
| Industry | Drug Manufacturers - Specialty & Generic |
| HQ | Saskatoon, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.zyus.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
874,442
Shares Sold
0
Total Transactions
8
SEDAR+ Filings
View All Filings7
Annual Reports
26
Quarterly Reports
33
MD&A
35
News Releases
9
Material Changes
6
Governance
66
Certifications
45
Other
Interactive Charts
Company Profile
General Information
| Company Name | ZYUS Life Sciences Corporation |
| Ticker | ZYUS.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Headquarters | Saskatoon, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.zyus.com |
Financial Summary
| Market Cap | 51.2M |
| Revenue | 481,000 |
| Net Income | -33.8M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.47 |
| Net Margin | -7028.1% |
| ROE | N/A |
| Dividend Yield | N/A |
Business Description
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.